CORRECTION: Weifa ASA: Record first-quarter revenues driven by organic growth
(Thomson Reuters ONE) -
Oslo, 27 April 2017
* Record first-quarter revenues of NOK 99.6 million (96.2 million)
* All-organic growth of 3.6%
* First quarter adjusted EBITDA of NOK 22.2 million (margin 22.3%)
* Strong brands secured revenue growth and high market shares in all main
categories
* Product-line expansion through the launch of Paracetduo effervescent
tablets and Nazamer Menthol nasal spray
Weifa ASA (OSE: WEIFA) had record first-quarter revenues in 2017 on higher sales
within the categories: pain relief, cough & cold products and dermatology, which
includes the Asan portfolio. Total revenues for the quarter was NOK 99.6
million, representing an all-organic growth of 3.6% compared with the same
period of 2016.
EBITDA was NOK 21.2 million (NOK 16.5 million) for the first quarter after NOK
1.0 million (NOK 5.5 million) in cost of employee options and other costs. The
EBITDA margin adjusted for these costs was 22.3% (22.8%). Weifa's portfolio of
long-established brands maintained a high market share in all key segments
during the quarter.
"We maintained a steady pace into 2017 with record first-quarter revenues. The
launch of Nazamér Menthol and Paracetduo effervescent tablets extended our
innovation track record, which together with rising demand for our main products
are a key driver for our long-term growth," says CEO Kathrine Gamborg
Andreassen.
Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter,
Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen
Nyberg-Hansen will represent the company. The presentation will also be webcast
live and can be accessed directly from:
http://webtv.hegnar.no/presentation.php?webcastId=51528850
http://www.weifa.no/webcast/
Questions may be submitted live during the presentation.
Please find the report and presentation for the first quarter enclosed. The
report and presentation will also be made available on www.weifa.no/investor.
For further information, please contact:
Kathrine Gamborg Andreassen
CEO
+47 9517 8680
kathrine.gamborg.andreassen(at)weifa.no
Simen Nyberg-Hansen
CFO
+47 9820 6355
simen.nyberg-hansen(at)weifa.no
Weifa is Norway's leading consumer health company. We supply real value through
medicines, lifestyle products and solutions that address the essential needs of
consumers, customers and professional partners. Weifa was founded in 1940 and
now employs about 30 highly qualified people at our headquarters in Oslo. The
company has a strong position in Norway and is the market leader in pain relief,
with well-established brands such as Paracet and Ibux. We are also present in
other key areas such as dietary supplements and treatment for colds and
respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For
further information, please visit: www.weifa.no
Weifa ASA_Q1 2017_Report:
http://hugin.info/136972/R/2099467/795553.pdf
Weifa ASA_Q1 2017_Presentation:
http://hugin.info/136972/R/2099467/795552.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2017 - 08:03 Uhr
Sprache: Deutsch
News-ID 538693
Anzahl Zeichen: 3799
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CORRECTION: Weifa ASA: Record first-quarter revenues driven by organic growth"
steht unter der journalistisch-redaktionellen Verantwortung von
Weifa ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
